Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phagerus
- Development stage
- Preclinical
- Lead developer
- iNtRON Biotechnology
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intranasal
01
Overview
Phagerus is a proprietary bacteriophage-based platform technology developed by iNtRON Biotechnology for the creation of antiviral vaccines and therapeutics. The platform employs a specialized CRISPR/Cas system to genetically engineer bacteriophages, allowing them to display viral antigens or virus-like particles (VLPs) on their capsids. These modified phages are designed to trigger both humoral (antibody-mediated) and cell-mediated immune responses against specific viral targets, such as the influenza virus. Phagerus-based products are intended for non-invasive administration via oral or nasal routes, leveraging the natural stability and bacterial-targeting properties of phages to enhance vaccine delivery and efficacy. Unlike traditional phage therapy which targets bacterial infections, Phagerus focuses on inducing immunity against viral pathogens while maintaining the original infectivity and bacterial control functions of the bacteriophage vector.
- Brand names
- Phagerus
02
Targets
Colibactin
Beyond the preview
Go deeper on Phagerus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phagerus.